The Approach: Informed Consent

As with testosterone therapy for trans men, there are two models for initiating feminizing hormone therapy: the traditional gatekeeper model requiring a mental health letter, and the informed consent model. I use informed consent for adults. ACOG supports this approach, stating that a thorough informed consent process without a separate mental health letter is adequate for initiating hormone therapy in adults who wish to medically transition, provided the key clinical elements are addressed.[1]

What informed consent means in practice is a substantive conversation — not a form. It covers the expected physical changes and their timeline, what is reversible and what isn't, the effect on fertility, the risks associated with treatment, monitoring requirements, and what surgery might involve if it becomes relevant later. I ask that patients have had persistent feelings of gender incongruence for at least a year before starting, to ensure we're acting on something stable rather than transient. The goal is a fully informed patient making a decision with real and lasting consequences.

📊 The Evidence — Why Treatment Matters Studies consistently show significant improvements in quality of life, psychological wellbeing, depression, and anxiety in transgender women who receive gender-affirming hormone therapy.[2][3] Withholding or delaying appropriate hormone therapy in patients who meet criteria has documented harms — including elevated rates of depression, anxiety, and suicidality.[2] The evidence supporting treatment is clear; the clinical question is how to do it well.

Fertility: The Conversation That Comes First

Estrogen therapy combined with anti-androgens suppresses sperm production, often substantially and sometimes irreversibly with long-term use. I discuss fertility with every patient before starting, regardless of age or stated plans about having children. Someone who is 24 and certain they never want biological children may feel differently at 35 — and sperm banking before starting therapy is a straightforward option that preserves that possibility. Once fertility is lost, it cannot be restored.

⚠ Fertility and Estrogen Therapy Estrogen plus anti-androgen therapy significantly reduces sperm production, often to the point where sperm are no longer detectable in semen. This effect may be reversible after stopping therapy, but recovery is not guaranteed — particularly after years of treatment. Sperm cryopreservation (sperm banking) before starting is the most reliable way to preserve fertility options, and it should be offered and discussed before the first prescription is written, not after.[2]

How Feminizing Hormone Therapy Works

Feminizing hormone therapy typically involves two components: estrogen to drive feminizing changes, and an anti-androgen to suppress testosterone production and its effects. The combination allows estrogen to work without being countered by the body's own testosterone.

Estrogen

Estradiol is the preferred form — bioidentical to the estrogen the body produces naturally. It can be delivered as an oral tablet, a transdermal patch or gel, or a subcutaneous or intramuscular injection. Transdermal and injectable routes avoid first-pass liver metabolism, which is relevant for the risk of blood clots (venous thromboembolism, or VTE) — a consideration discussed further below. The target is estradiol levels in the normal female physiologic range (typically 100–200 pg/mL), not above it.[2]

Anti-Androgens

In the United States, the most commonly used anti-androgens are spironolactone and, increasingly, bicalutamide. Spironolactone is a diuretic that also blocks androgen receptors and reduces testosterone production; it's inexpensive and widely available, though it requires monitoring of potassium levels. Bicalutamide blocks androgen receptors directly without the diuretic effects. In some patients — particularly those who have had orchiectomy — anti-androgens are not needed once testosterone production is eliminated surgically. This is a clinically useful option for patients who struggle to tolerate spironolactone due to elevated potassium, low blood pressure, or other side effects: orchiectomy removes the need for ongoing anti-androgen therapy entirely.[2][3]

GnRH agonists (such as leuprolide) are a more complete option that suppress both testosterone and the pituitary signaling driving its production, but cost and availability limit their use in adult feminizing protocols compared to their more common use in adolescent puberty suppression.[2]

What to Expect: Physical Changes and Timeline

Changes from feminizing hormone therapy occur gradually over months to years. Setting realistic expectations about timeline — and about which changes are permanent — is one of the most important parts of the pre-treatment conversation.

1–3 months

Early changes

  • Decreased libido and spontaneous erections
  • Breast budding begins — often tender initially
  • Skin becomes softer and less oily
  • Decreased testicular volume begins
  • Subtle fat redistribution begins
3–6 months

Ongoing feminization

  • Continued breast development
  • Fat redistributing toward hips, thighs, and face
  • Reduced body hair growth rate and density
  • Reduced muscle mass and strength
  • Mood changes as hormone levels stabilize
6–24 months

Continued and slower changes

  • Breast development continues — most growth occurs in first 2 years
  • Further fat redistribution
  • Body hair continues thinning
  • Scalp hair may begin to regrow if loss was early-stage
Beyond 2 years

Stabilization

  • Most physical changes plateau — the degree of feminization achieved by 2 years is largely the final result
  • Ongoing maintenance dosing continues

Reversibility — What Stops When Estrogen Stops

Change Reversibility
Decreased libido and erections Reversible
Skin softening, reduced oiliness Reversible
Fat redistribution Partially reversible
Reduced muscle mass Partially reversible
Body hair reduction Partially reversible — some regrowth but often not full
Breast development Largely irreversible — breast tissue does not fully regress
Testicular atrophy Largely irreversible after prolonged therapy
Fertility reduction Uncertain — may recover, not guaranteed
Facial bone structure Not affected by hormones — only surgical modification changes this

Monitoring: What Gets Checked and Why

⚠ Monitoring Schedule
  • Every 3 months in year one: Estradiol level, testosterone level, potassium (if on spironolactone), clinical assessment of feminizing progress and side effects
  • Every 6–12 months thereafter: Same hormone levels, lipids, weight, blood pressure
  • Estradiol target: 100–200 pg/mL — normal female physiologic range
  • Testosterone target: Below 50 ng/dL — suppressed into female range

Health Risks to Understand Before Starting

Venous Thromboembolism — The Most Important Risk

The most significant health risk associated with feminizing hormone therapy is venous thromboembolism (VTE) — blood clots, including deep vein thrombosis and pulmonary embolism. Estrogen increases clotting factor production in the liver, particularly with oral formulations that undergo first-pass hepatic metabolism. This is the same mechanism that elevates VTE risk in cisgender women on combined oral contraceptives.

📊 The Evidence — VTE Risk

Older studies using high-dose synthetic estrogens showed substantially elevated VTE risk. More recent data using bioidentical estradiol at physiologic doses show a more modest elevation — the risk is real but substantially lower than with older regimens.[2][3] Transdermal and injectable estradiol carry lower VTE risk than oral estrogen because they bypass the liver's first-pass effect on clotting factors, consistent with what we see in cisgender women on HRT.[2]

Risk factors that increase VTE concern include personal or family history of clotting disorders, obesity, smoking, prolonged immobility, and surgery. Screening for thrombophilia before starting is appropriate in women with a personal or family history of unexplained blood clots.[2]

Cardiovascular and Metabolic Effects

Estrogen therapy improves the lipid profile — raising HDL and lowering LDL — which is favorable from a cardiovascular standpoint. Blood pressure should be monitored, particularly in patients on spironolactone, which lowers blood pressure. Long-term cardiovascular outcomes data in transgender women are limited but generally reassuring at physiologic estradiol doses.[2]

Prolactin and Breast Health

Estrogen stimulates prolactin production from the pituitary. Prolactin levels are checked at baseline and monitored periodically, particularly in patients on higher doses, as rarely estrogen therapy can contribute to pituitary adenoma growth. Baseline prolactin before starting is standard practice.[2]

Cancer Screening

Routine cancer screening should continue based on the anatomy each patient has. Trans women who have not had orchiectomy should be aware that prostate tissue remains present — prostate cancer screening discussions apply. Those who develop meaningful breast tissue on hormone therapy should discuss mammography timing with their provider. Affirming care includes making sure patients feel comfortable accessing these conversations without barriers.

Surgery: A Separate Decision on a Different Timeline

Hormone therapy and gender-affirming surgery are independent decisions. I recommend approximately 12 months of hormone therapy before considering surgical referral — not as a gatekeeping requirement, but because that period allows the body to respond to hormones, gives patients lived experience with the changes, and helps clarify which surgical interventions, if any, are the right fit. Surgical referral standards typically require documentation from mental health professionals, and genital surgery usually involves additional criteria around duration of hormone therapy and living in the affirmed gender role.[2]

My Synthesis Feminizing hormone therapy is one of the areas of my practice where the benefit-to-risk ratio is clearest for appropriate patients. The evidence on quality of life and mental health outcomes is consistent and compelling. My approach is informed consent — substantive, honest, and patient-centered — not gatekeeping. A patient who has thought carefully about this, understands what is reversible and what isn't, has addressed fertility, and has no major contraindications is ready to start.

The two conversations I'm most careful about are fertility — because the potential consequences are permanent and the decision to bank sperm is time-sensitive — and VTE risk, because it's the most significant medical risk and it's meaningfully reduced by choosing transdermal or injectable estradiol over oral. Those two things covered, the rest is individualized monitoring and ongoing clinical partnership.